NewLimit Series C raises $435M led by Founders Fund as Armstrong-backed startup moves epigenetic therapies toward human ...

NewLimit Raises $435M to advance longevity medicine trials, expand ageing research programmes and accelerate clinical growth.

Researchers at Oregon Health & Science University have uncovered a key reason why immunotherapy has largely failed in pancreatic cancer—and identified a promising strategy to overcome that resistance.

Company has now raised $6 million since founding to advance mRNA-based therapeutics designed to turn tumor cells into immune-activating cellsSAN CARLOS, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- ...

Solid tumors often provide a challenging environment for the T cells of our immune system. By reprogramming the metabolism of T cells, scientists at the VIB-KU Leuven Center for Cancer Biology and ...

Announcing a new article publication in BIO Integration. Pulmonary fibrosis (PF) is a progressive and irreversible ...

Cancer immunotherapy has advanced the field of medicine and cancer care. Specifically, immunotherapy refers to the targeted treatment of the immune system. Over the last few decades, immunotherapy has ...

A team led by researchers has discovered that a group of cells located in the skin and other areas of the body, called neural crest stem cells, are the source of reprogrammed neurons found by other ...

A new way of reprogramming our immune cells to shrink or kill off cancer cells has been shown to work in the otherwise hard to treat and devastating skin cancer, melanoma. The discovery demonstrates a ...

Reprogramming requests requiring congressional approval currently take between four and six months. This accounts for the time from a reprogramming request being identified by the DoD to it being ...